Here's a classic Wall Street head-scratcher: a company reports earnings that blow past expectations, raises its full-year guidance, and announces a shiny new partnership—and its stock promptly falls. That's exactly what happened to CVS Health Corp. (CVS) on Wednesday.
Shares of the healthcare giant were down 6.49% at $97.64 at the time of publication, according to market data. The likely culprit? Profit-taking. The stock had rallied nearly 60% since the end of the first quarter, so some investors decided to cash in their chips despite the good news.
Let's break down what CVS actually delivered, because there's a lot to unpack here.
The Numbers Were Strong
CVS reported adjusted earnings of $2.58 per share, crushing the analyst consensus of $1.85. Revenue came in at $106.10 billion, up 7.3% year over year and well above the $100.11 billion analysts were looking for. Adjusted operating income jumped 35.4% to $5.16 billion, with growth across all operating segments.
The Health Care Benefits segment—which includes Aetna—saw revenue rise 3.5% to $37.54 billion, driven by growth in the government business, though that was partially offset by the company's exit from the individual exchange business in 2026. The medical benefit ratio improved to 87.4% from 89.9% a year earlier, reflecting stronger performance in the government business and the absence of a premium deficiency reserve that had weighed on the prior-year period. Medical membership dipped to 26.02 million from 26.72 million.
The Health Services segment, which includes pharmacy benefit management, posted an 11.5% revenue increase to $51.80 billion, helped by improved purchasing economics, changes in pharmacy drug mix, and modest improvement in the health care delivery business. Meanwhile, the Pharmacy & Consumer Wellness segment saw revenue edge up to $33.82 billion, with prescriptions filled rising 4.3% to 457 million.
Guidance Goes Up
Looking ahead, CVS raised its fiscal 2026 adjusted earnings guidance to a range of $7.90 to $8.10 per share, up from its previous outlook of $7.30 to $7.50. That new range sits comfortably above the analyst consensus of $7.45. The company also expects fiscal 2026 revenue to exceed $414 billion, compared with the consensus estimate of $409.24 billion.
CVS reaffirmed its expectation for a 2026 medical benefit ratio of 89.75%, plus or minus 25 basis points, describing it as “a respectful and prudent view of medical cost trends in the second half of the year.”
But it wasn't all sunshine. During the earnings call, management said it expects ongoing market dynamics in its 340B business to remain a headwind in 2027, and it anticipates membership declines in its Caremark pharmacy benefit management business next year. So while the near-term picture looks good, there are some clouds on the horizon.
The GLP-1 Play
In a separate announcement, CVS unveiled an expanded weight management platform designed to make GLP-1 therapies more accessible. The idea is to combine virtual clinical care, pharmacy services, and medication pricing support into one streamlined experience.
As part of this, CVS is partnering with Eli Lilly and Company (LLY) to provide eligible Zepbound and Foundayo patients with transparent pricing through the CVS Health app. Starting in early fourth quarter 2026, eligible users will be able to see insurance and cash-pay pricing and access same-day pickup at approximately 9,000 CVS Pharmacy locations.
CVS also introduced a $29 virtual MinuteClinic visit, allowing eligible patients to consult licensed clinicians who can evaluate and prescribe GLP-1 therapies when clinically appropriate. And for those worried about cost, the company said eligible commercially insured patients may pay as little as $25 per month with manufacturer coupons, while qualifying uninsured patients may access certain GLP-1 medications for $149 using manufacturer vouchers.
This is a smart move. GLP-1 drugs are all the rage, but affordability and access have been major hurdles. By partnering with Lilly and leveraging its own pharmacy network, CVS is positioning itself as a one-stop shop for weight management—which could drive foot traffic and prescription volume.
So, why did the stock fall? Sometimes the market just needs a breather. After a 60% run, some investors are happy to take profits. The long-term story here—strong earnings, raised guidance, and a growing GLP-1 platform—remains intact. But as always, the market does what it wants.
